No OS ben­e­fit? No prob­lem. FDA pan­el backs use of Lyn­parza in pan­cre­at­ic can­cer

6 years ago
FDA+

Boehringer dumps its $250M NASH drug; Bavar­i­an Nordic sells PRV for $95M; GBT inks deal with Sy­ros, gets $150M loan

6 years ago
News Briefing

Oh Cana­da! There is no San­ta Claus to the north giv­ing out cheap drugs to US pa­tients

6 years ago
Bioregnum
R&D

ARCH-backed biotech emerges with $85M and a bold claim: A new hu­man hor­mone can re­verse a key ef­fect of ag­ing

6 years ago
R&D

Psy­che­del­ic re­search gains mo­men­tum, as ear­ly tri­al sug­gests mi­cro-dos­ing LSD is safe

6 years ago
R&D

Canaan backs Pathios' search for small mol­e­cule drugs that hit 'or­phan' GCPR

6 years ago
Financing
Startups

FTC calls out Il­lu­mi­na as 'mo­nop­o­list,' moves to block $1.2B ac­qui­si­tion of PacBio

6 years ago
Deals

Af­ter tak­ing a hard look at the da­ta, No­var­tis punts Aduro’s STING drug — the lat­est in a long line of set­backs

6 years ago
R&D

David Meek hands in his CEO ti­tle at Ipsen, leap­ing across the At­lantic to run a start­up prep­ping its first US drug ...

6 years ago
People

No pain, no gain: Com­pa­ny-build­ing French VC scores €250M for life sci­ences fund

6 years ago
Financing
Startups

FDA sur­vey finds Amer­i­cans don’t re­al­ly un­der­stand drug ap­provals

6 years ago
FDA+

Eli Lil­ly spot­lights ear­ly on­col­o­gy in first pipeline re­view since R&D shift

6 years ago
R&D

Im­muno­Gen maps new path to ac­cel­er­at­ed ap­proval; BioN­Tech scores €50M fund­ing from Eu­ro­pean bank

6 years ago
News Briefing

Ver­sus Ver­tex, Pro­teosta­sis' triplet CF da­ta fall short, wilt­ing stock

6 years ago
R&D

Bio­haven cel­e­brates PhII/III win for in­tranasal CGRP mi­graine drug amid oral race with Al­ler­gan

6 years ago
R&D

FDA’s in-house re­view of­fers bleak as­sess­ment of Epizyme’s tazeme­to­stat — but win or lose this can­cer drug may ...

6 years ago
R&D
FDA+

Seer rais­es $55M as pro­teomics ap­proach­es prime time in dis­ease de­tec­tion, drug de­vel­op­ment

6 years ago
R&D

Promis­es made, promis­es kept: Al­ny­lam CEO John Maraganore adds 3rd straight pos­i­tive piv­otal as he aims at an­oth­er ...

6 years ago
R&D

In crowd­ed prostate can­cer mar­ket, Pfiz­er's Xtan­di notch­es third ap­proval for use in ear­li­er stage of dis­ease

6 years ago
R&D
FDA+

What uni­fies Hunt­ing­ton's, spin­ocere­bel­lar atax­ia and my­oton­ic dy­s­tro­phy? Ness Berming­ham's new start­up looks to drug ...

6 years ago
Financing
Startups

GSK poised to leap back in­to the on­col­o­gy mar­ket with more pos­i­tive be­lan­tam­ab mafodotin re­sults — but BC­MA ri­vals ...

6 years ago
R&D

FTC to Roche: OK, go ahead and com­plete your $4.3B Spark buy­out — we're con­vinced now this is­n't an­ti­com­pet­i­tive

6 years ago
R&D

In­side Astel­las' $3B Au­dentes gene ther­a­py ac­qui­si­tion: cod­ed mes­sages, a bid­ding war and $77M for the CEO

6 years ago
Deals
Cell/Gene Tx

Charles Riv­er Labs forks over $380M cash for cell ther­a­py play­er; Ax­some soars on PhI­II de­pres­sion read­out

6 years ago
News Briefing
First page Previous page 883884885886887888889 Next page Last page
A service from the Financial Times